CTBP2 and prostate carcinoma: Using the Cancer Genome Atlas (TCGA) dataset, we observed that high expression of CTBP2 was significantly correlated with poor overall survival of prostate cancer patients (Fig. 4A), while AKAP12, HIF1A and RHOB were not.